Inhalable DNase I microparticles engineered with biologically active excipients

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2013, Pages 700-709

  Osman, Rihab ^a,b   Al Jamal, Khuloud T ^a,c   Kan, Pei Lee ^a   Awad, Gehanne ^b   Mortada, Nahed ^b   EL Shamy, Abd Elhameed ^b   Alpar, Oya ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b African Union Organization St Abbassia   (Egypt)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cystic fibrosis; Dextran; DNase I; Leucine; Polyanions; Pulmonary

Indexed keywords

CHITOSAN; DEOXYRIBONUCLEASE I; DEXTRAN; EXCIPIENT; LIPID; OVALBUMIN; POLYGLACTIN; SURFACTANT;

AEROSOL; ANGLE OF REPOSE; ANIMAL CELL; ARTICLE; BIOCOMPATIBILITY; BIOLOGICAL ACTIVITY; COATED PARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DENATURATION; ENCAPSULATION; ENZYME STABILITY; GLASS TRANSITION TEMPERATURE; HYDROPHILICITY; HYDROPHOBICITY; INHALATION; LUNG; LUNG ALVEOLUS EPITHELIUM; MACROMOLECULE; MACROPHAGE; MATERIAL STATE; MICROPARTICLE; MOUSE; MUCUS; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; POWDER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SURFACE PROPERTY; SUSTAINED RELEASE FORMULATION; VISCOSITY; WATER CONTENT; ZETA POTENTIAL;

CYSTIC FIBROSIS; DEXTRAN; DNASE I; LEUCINE; POLYANIONS; PULMONARY;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; CHITOSAN; CYSTIC FIBROSIS; DELAYED-ACTION PREPARATIONS; DEOXYRIBONUCLEASE I; DEXTRANS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; EXCIPIENTS; LACTIC ACID; MACROPHAGES; MICE; MUCUS; OVALBUMIN; POLYGLUTAMIC ACID; POLYGLYCOLIC ACID; POWDERS; VISCOSITY;

EID: 84887990979     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.07.010     Document Type: Article

References (42)

1. Sheppard M.N., Nicholson A.G. The pathology of cystic fibrosis. Cur Diag Pathol 2002, 8:50-59.
2. Cipolla D.C., Clark A.R., Chan H.K., Gonda I., Shire S.J. Assessment of aerosol delivery systems for the recombinant human deoxyribonuclease I (rhDNase). STP Pharm Sci 1994, 4:50-62.
3. Gonda I. Inhalation therapy with recombinant human deoxyribonuclease I. Adv Drug Deliv Rev 1996, 19:37-46.
4. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009, 61:158-171.
5. Suk J.S., Lai S.K., Wang Y.Y., Ensign L.M., Zeitlin P.L., Boyle M.P., et al. The penetration of fresh diluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30:2591-2597.
6. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 2004, 1:315-320.
7. Rabbani N.R., Seville P.C. The influence of formulation components on the aerosolisation properties of spray-dried powders. JControl Release 2005, 110:130-140.
8. Bosquillon C., Lombry C., Preat V., Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. JControl Release 2001, 70:329-339.
9. Learoyd T.P., Burrows J.L., French E., Seville P.C. Modified release of beclomethasone dipropionate from chitosan-based spray-dried respirable powders. Powder Tech 2008, 187:231-238.
10. Kaye R.S., Purewal T.S., Alpar H.O. Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies. JPharm Sci 2009, 9999:1-14.
11. Shoyele S.A., Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 2006, 58:1009-1029.
12. Jones S.A., Martin G.P., Brown M.B. Stabilisation of deoxyribonuclease in hydrofluoroalkanes using miscible vinyl polymers. JControl Release 2006, 115:1-8.
13. Elkordy A.A., Forbes R.T., Barry B.W. Study of protein conformational stability and integrity using calorimetry and FT-Raman spectroscopy correlated with enzymatic activity. Eur J Pharm Sci 2008, 33:177-190.
14. Maa Y.F., Nguyen P.A., Hsu C.C. Spray-coating of rhDNase on lactose: effect of system. Int J Pharm 1996, 144:47-59.
15. Chan H.K., Clark A., Gonda I., Mumenthaler M., Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rh DNase) for aerosol delivery. Pharm Res 1997, 14(4):431-437.
16. Tang J.X., Wen Q., Bennett A., Kim B., Sheils C.A., Bucki R., et al. Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum. Am J Physiol Lung Cell Mol Physiol 2005, 289:L599-L605.
17. Feng W., Garret W.H., Speert D.P., King M. Improved clearability of cystic fibrosis sputum with dextran treatment invitro. Am J Respir Crit Care Med 1998, 157:710-714.
18. Feng W., Nakamura S., Sudo E., Lee M.M., Shao A., King M. Effects of dextran ontracheal mucociliary velocity in dogs invivo. Pulm Pharm Ther 1999, 12:35-41.
19. Barghouthi S., Guerdoud L.M., Speert D.P. Inhibition by dextran of Pseudomonas aeruginosa adherence to epithelial cells. Am J Respir Crit Care Med 1996, 154:1788-1793.
20. Bryan R., Feldman M., Jawetz S., Rajan S., DiMango E., Scheffler L., et al. The effects of aerosolized dextran in a mouse model of Pseudomonas aeruginosa pulmonary infection. JInfect Dis 1999, 179:1449-1458.
21. Evora C., Soriano I., Rogers R.A., Shakesheff K.M., Hanes J., Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. JControl Release 1998, 51:143-152.
22. Jones B.J., Dickinson P.A., Gumbleton M., Kellaway I.W. The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages. Int J Pharm 2002, 236:65-79.
23. Orienti I., Cerchiara T., Luppi B., Bigucci F., Zuccari G., Zecchi V. Influence of different chitosan salts on the release of sodium diclofenac in colon-specific delivery. Int J Pharm 2002, 238:51-59.
24. Tan S.B., Newton J.M. Powder flowability as an indication of capsule filling performance. Int J Pharm 1990, 61:145-155.
25. Staniforth J.N. Powder flow. Pharmaceutics: the science of dosage form design 2002, 207-208. Churchill Livingstone, Edinburgh, London, New York, Philadelphia, St Louis, Sydney, Toronto. 2nd ed. M.E. Aulton (Ed.).
26. Florindo H.F., Pandit S., Gonçalves L.M.D., Alpar H.O., Almeida A.J. Streptococcus equi antigens adsorbed onto surface modified poly-γ-caprolactone microspheres induce humoral and cellular specific immune responses. Vaccine 2008, 26:4168-4177.
27. Jeffery H., Davis S.S., O'Hagan D.T. The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res 1993, 10(3):362-368.
28. Osman R., Kan P.L., Awad G., Mortada N., EL-Shamy A., Alpar O. Enhanced properties of discrete pulmonary deoxyribonuclease I (DNase I) loaded PLGA nanoparticles during encapsulation and activity determination. Int J Pharm 2011, 408:257-265.
29. Nadano D., Yasuda T., Kishi K. Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method. Clin Chem 1993, 39(3):445-452.
30. Broughton-Head V.J., Smith J.R., Shur J., Shute J.K. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm Pharm Ther 2007, 20:708-717.
31. Nakate T., Yoshida H., Ohike A., Tokunaga Y., Ibuki R., Kawashima Y. Formulation development of inhalation powders for FK888 using the E-haler to improve the inhalation performance at a high dose and its absorption in healthy volunteers. Eur J Pharm Biopharm 2005, 59:25-33.
32. Florindo H.F., Pandit S., Lacerda L., Gonçalves L.M.D., Alpar H.O., Almeida A.J. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-ε-caprolactone-based nanoparticles. Biomaterials 2009, 30:879-891.
33. Tomoda K., Makino K. Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres. Colloids Surf B Biointerfaces 2007, 55:115-124.
34. Maury M., Murphy K., Kumar S., Mauerer A., Lee G. Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur J Pharm Biopharm 2005, 59:251-261.
35. Najafabadi A.R., Gilani K., Barghi M., Rafiee-Tehrani M. The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with l-leucine. Int J Pharm 2004, 285:97-108.
36. Fineberg S.E., Krasner A.S., Fineberg N.S. Insulin antibodies with pulmonary delivery of insulin. Tech Ther 2007, 9:S102-S110.
37. Vehring R., Foss W.R., Lechuga-Ballesteros D. Particle formation in spray drying. Aerosol Sci 2007, 38:728-746.
38. Raula J., Lähde A., Kauppinen E.I. Anovel gas phase method for the combined synthesis and coating of pharmaceutical particles. Pharm Res 2008, 25(1):242-245.
39. Chan H.K. Dry powder aerosol drug delivery-Opportunities for colloid and surface scientists. Colloids Surf A Physicochem Eng Asp 2006, 284-285:50-55.
40. Masters K. Spray-drying handbook 1991, Longman Scientific and Technical, Harlow, England. 5th ed.
41. Maa Y., Hsu C. Protein denaturation by combined effect of shear and air- liquid interface. Biotechnol Bioeng 1997, 54:503-512.
42. Chew N.Y.K., Chan H.K. Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res 2001, 18(11):1570-1577.